Results 11 to 20 of about 94,073 (238)
Haematologica, 2011 Within a cohort of 1,915 consecutive patients with myeloproliferative neoplasm followed for a median time of 5.2 years (range 0–33.3), we investigated the occurrence of lymphoid neoplasm with the aim of defining this risk and to investigate the role of ...
Elisa Rumi +9 more
doaj +2 more sources
Acta Medica, 2010 Neutrophilic dermatosis of the dorsal hands is a variant of Sweet's syndrome. We herein describe an 83-year old woman with a neutrophilic dermatosis of the dorsal hands associated with a "myeloproliferative neoplasm, unclassifiable" and a simultaneous ...
Francisco José Fernández-Fernández +4 more
doaj +2 more sources
Autoimmunity and the risk of myeloproliferative neoplasms
Haematologica, 2010 The causes of myeloproliferative neoplasm (MPN) are unknown. We conducted a large population-based study including 11,039 myeloproliferative neoplasm patients and 43,550 matched controls with the aim of assessing the associations between a personal ...
Sigurdur Y. Kristinsson +4 more
doaj +2 more sources
IL-4 Serum Level Estimation in Myeloproliferative Neoplasm Patients [PDF]
مجلة مركز بحوث التقنيات الاحيائية, 2022 Back Ground: Myeloproliferative neoplasm (MPN) is a long-term blood disease that has an excess production of mature hematopoietic pluripotent stem cells in the bone marrow. In the early fifties, W.
Ahmed Rushdi Abdullah
doaj +2 more sources
Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency [PDF]
Haematologica, 2016 Juvenile myelomonocytic leukemia is a rare myeloproliferative neoplasm characterized by hyperactive RAS signaling. Neurofibromin1 (encoded by the NF1 gene) is a negative regulator of RAS activation.
Zohar Sachs +16 more
doaj +2 more sources
, 2021 Supplementary Table from LKB1/STK11 Is a Tumor Suppressor in the Progression of Myeloproliferative ...
John D. Crispino (15025091) +24 more
core +6 more sources
eJHaemCasitas B‐cell lineage (CBL) syndrome is a rare RASopathy known to predispose to CBL‐mutated juvenile myelomonocytic leukemia (JMML) in childhood. Adulthood acute myeloid leukemia arising out of a genetic aberrancies consistent with prior CBL‐mutated ...
George Mason +6 more
doaj +2 more sources
The Microenvironment in Myeloproliferative Neoplasms [PDF]
Hematology/Oncology Clinics of North America, 2021 Chronic inflammation is a hallmark of myeloproliferative neoplasms (MPNs), with elevated levels of proinflammatory cytokines being commonly found in all 3 subtypes. Systemic inflammation is responsible for the constitutional symptoms, thrombosis risk, premature atherosclerosis, and disease evolution in MPN.
Ramanathan, Gajalakshmi +1 more
openaire +3 more sources
Myeloproliferative neoplasms [PDF]
Clinical Medicine, 2013 The myeloproliferative neoplasms that are associated with the JAK2 mutation are a heterogeneous group of disorders. The additional mutations that result in the clinical phenotype are still the subject of research. As more than one mutation is involved, and as JAK2 has a necessary physiological role (unlike BCR-ABL), the development of targeted therapy ...
Amy, Publicover, Patrick, Medd
openaire +3 more sources
Morphology of myeloproliferative neoplasms
International Journal of Laboratory Hematology, 2023 AbstractMyeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies first described by Dameshek in 1957. The Philadelphia‐negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre‐fibrotic myelofibrosis and primary myelofibrosis (PMF).
Zi Yun Ng +3 more
openaire +2 more sources